Novavax outlines $1.04B–$1.06B 2025 revenue framework and targets non-GAAP profitability as early as 2028 amid partnership-driven transition
View original at seekingalpha.comNovavax outlines $1.04B–$1.06B 2025 revenue framework and targets non-GAAP profitability as early as 2028 amid partnership-driven transition Earnings Call Insights: Novavax (NVAX) Q3 2025 MANAGEMENT VIEW * John Jacobs, President, CEO & Director, stated that Novavax has made significant progress in Q3 by strengthening e…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
2025 priorities include optimizing Sanofi partnership, enhancing existing partnerships, leveraging technology platform for additional partnerships, and advancing technology platform and early-stage pipeline
80% confidenceFor 2026, Novavax previews adjusted total revenue expectations between $185 million and $205 million, driven in part by $75 million milestone from manufacturing technology transfer to Sanofi
80% confidenceNovavax reduced almost $1 billion in operating expenses between 2022 and 2024
80% confidenceNovavax brought in $60 million in near-term cash from consolidating Maryland sites
80% confidenceThe non-GAAP profitability target has shifted to 2028 due to updated timelines for Sanofi's combination programs
80% confidenceNovavax recorded $126 million in noncash charges in Q3 related to site consolidation and debt refinancing
80% confidenceNovavax reported total revenue of $70 million in Q3 2025
80% confidenceMaryland campus consolidation brought in $60 million in near-term cash and anticipated long-term savings of approximately $230 million
80% confidenceNovavax intends to take a conservative position as they communicate with investors
80% confidenceNovavax uses a stage-gate approach for early-stage pipeline strategy and intends to partner pipeline assets
80% confidenceNovavax removed more than $1 billion of current liabilities by year-end 2024 compared to 2022
80% confidenceThe $75 million 2026 milestone is tied to manufacturing tech transfer completion with Sanofi
80% confidenceThe BARDA grant supports Sanofi's pandemic flu vaccine candidate using Novavax's Matrix-M adjuvant
80% confidenceNovavax uses rigorous comparator testing in preclinical programs
80% confidenceThe $25 million revenue increase is driven by $7.5M increase to adjusted supply sales, $12.5M increase to Sanofi cost reimbursement, and $5M increase to other partner revenue
80% confidenceNovavax reaffirms full year 2025 combined R&D and SG&A expenses of $520 million at midpoint, narrowing range to $505M-$535M
80% confidenceOver the past 8 quarters, Novavax achieved approximately $1.1 billion in nondilutive cash flow, including $800 million from partnerships
80% confidenceNovavax reaffirms multiyear targets for 2026 and 2027 combined R&D and SG&A expenses, net of partner reimbursements, of $350 million and $250 million respectively
80% confidenceQ3 2025 combined R&D and SG&A costs were reduced by 18% compared to same period last year
80% confidenceThe COVID market in the U.S. is down about 20% compared to last year due to policy changes and label alignment
80% confidenceOn non-GAAP basis, net of partner reimbursement, full year 2025 R&D and SG&A expected to be approximately $450 million at midpoint
80% confidenceMatrix-M partner evaluations are ongoing experiments that are shorter than years, not years and years down the road
80% confidence